Structured around translating opportunities from university laboratories into proof-of-concept or clinical-ready packages for the pharma/biotech industry, Bessor Pharma LLC management are using an innovative technology and business model for new drug development and value creation. Drawing down on in-house experience and management skills, along with a diverse range of connections and capital markets know-how, the effort si to create and foster an ecosystem of academic and industry partners as key stakeholders facilitating translational R&D. Bessor personnel bring to the table a track record accumulated by management in drug development; operational progress; and a range of collaborative partnerships to fuel a pipeline of needed drugs. The company's team and advisors have (individually and ccollectively) been instrumental in development of a range of drugs alraedy in-use - to include Tykerb® (lapatinib), Gemzar® (gemcitabine), Coreg (carvedilol), and Corlopam® (fenoldopam). The company is further developing products that address immune inflation, including pancreatitis/acute kidney injury and ocular inflammatory conditions. Undertaking projects in the immuno-oncology space: pancreatic cancer, melanoma, and chemotherapy tissue damage, various personnel are also working in stem cell signaling, focusing on traumatic brain injury and concussion, as well as periodontal and cardiovascular disease.
